Farmacias Benavides S.A.B. de C.V.

What it is

Farmacias Benavides has been in business for more than a century and operates in 200 cities across 27 Mexican states, with a network of over 1,100 pharmacies and 450 in-store medical consultation rooms. Its roughly 8,000 staff sell a catalogue of more than 11,000 products — branded goods and its own private labels — focused on health and everyday wellness.

Alongside prescription and over-the-counter drugs, it provides lab sample collection, home delivery, an online pharmacy, and even photo-processing services. The company started life in 1917 in Monterrey as Botica del Carmen, a single apothecary, and grew over the following decades into northern and western Mexico’s dominant pharmacy chain.

Who owns it

The parent is Walgreens Boots Alliance (WBA), the US-listed global pharmacy group, which holds 95.6% of the shares — leaving a free float of barely 4.4% trading on the BMV. In August 2025, Sycamore Partners, a US private-equity firm, completed its acquisition of WBA, taking it private; Stefano Pessina and his family reinvested 100% of their WBA interest alongside Sycamore.

Benavides contributes roughly 0.75% of WBA’s annual revenues — small enough that a future disposal of the Mexican unit has been openly discussed, though nothing has been announced. For the moment, Benavides changes hands indirectly every time its parent’s ownership does.

Who runs it

Mauricio González-Luna Gutiérrez-Lascuráin became chief executive (Director General) on 2 December 2024, replacing Michele Antonio Ingravallo, who moved up to a global retail role at WBA. González-Luna brings 30 years in the pharmacy industry and had already led parts of Benavides between 2017 and 2023.

The finance director position has also turned over recently: José Alfonso Salazar Montalvo was named CFO in early 2026, succeeding Ana Clarisa Victoria Magallanes. Salazar Montalvo brings two decades of finance experience from companies including Heinz and Gonher.

The money, in plain words

Sales grew from MXN 14.7 bn (US$849 m) in 2021 to MXN 17.2 bn (US$994 m) in 2023 — a rise of 16.8% over two years (our calculation) — driven by store expansion and the addition of in-store doctors’ surgeries. The gross margin, what is left after buying the goods it sells, was 30.7% in 2023 (our calculation) — reasonable for a pharmacy chain that competes partly on price.

The bottom line tells a tougher story: the company kept only about 2.2 cents of profit from every peso of sales (net profit margin, 2.2% on a trailing basis), thin even by drugstore standards. Benavides’s auditors have flagged a standing concern: its short-term liabilities exceed its short-term assets — meaning that on paper it owes more in the near term than it can immediately collect.

The return on equity of 59.8% looks spectacular, but is partly a consequence of that razor-thin equity base: owners have very little capital tied up, so even modest profits produce a high percentage return.

The stock trades at 37.7 times earnings (price-to-earnings ratio of 37.7×) — elevated for a low-margin retailer — and pays no dividend. Cash on the 2023 balance sheet was MXN 677 m (US$39 m), with no debt separately disclosed (our calculation).

What it is doing now

The company’s four stated strategic pillars are store expansion, in-store medical clinics, own-brand products, and its customer loyalty programme. The loyalty scheme — which offers free medicines and special promotions — has grown steadily and is described by management as a key differentiator in a crowded market.

The biggest immediate event is at the parent level: Sycamore Partners completed its acquisition of WBA in August 2025, placing Benavides under new ultimate ownership with no stated change to its day-to-day operations. Leadership has simultaneously turned over at both the chief executive and finance director level within the past six months.

What to watch

• Sale or spin-off risk. Benavides generates around 0.75% of WBA’s revenues — Sycamore could rationalise its new portfolio and sell or list the Mexican business separately.
• Liquidity. Auditors have consistently flagged that current liabilities exceed current assets; new management must either refinance or generate more operating cash to close that gap.
• Margin recovery. At 2.2% net margin and a P/E of 37.7×, the market is paying a growth premium; if margins do not widen as the clinic and own-brand strategies mature, the valuation is hard to justify.
• Leadership continuity. Three finance directors in less than 18 months is worth watching; stability in the CFO seat is a precondition for any serious recapitalisation or sale process.

This is news, not investment advice.